Baird has upgraded Quest Diagnostics (NYSE:DGX) from Neutral to Outperform, raising its price target from $157 to $182, citing favorable industry trends and the company's strong positioning for growth. The firm anticipates stable pricing, core volume growth, and increased acquisition activity, alongside a solid financial performance with a market cap of $17.64 billion and a P/E ratio of 19.82. Quest Diagnostics has also maintained a consistent dividend policy, enhancing its appeal to investors.